Visualize HL7 Example and Test Instances (vi7eti), pronounced /viːˈsɛtiː/
Disclaimer: FOR TEST AND EXAMPLE PURPOSES ONLY! These web pages are not intended to be used as a source of information on on healthcare or medicines. The web pages are not kept up to date and are for demonstration purposes only. For up-to-date information on a medicine, please consult www.ema.europa.eu/medicines or the package leaflet of your medicine. For up-to-date information on other healthcare topics, please consult the relevant reliable sources or an healthcare expert, such as a physician etc.
 BACK TO LIST

European Patient Summary

Patient
Name: Naranjo, Noé
DOB: 22-JAN-1943 (Age: 82)
Gender: male
ID: 4002-059080-4 (ECI)
Author
Dr. Ping, Hel
Patient summary Document
European Patient Summary
Report Date: 19-JUL-2025

Problem list

Condition Onset Date Status
Osteoporosis 04-Feb-2019 active
Alzheimer's disease 17-Oct-2014 active
Dependent drug abuse 27-Apr-2014 active
Acute ST segment elevation myocardial infarction 17-May-2011 active
Chronic kidney disease stage 2 15-Sep-2007 active
Microalbuminuria due to type 2 diabetes mellitus 15-Sep-2007 active
Disorder of kidney due to diabetes mellitus 24-Nov-2001 active
Chronic kidney disease stage 1 24-Nov-2001 active
Hyperglycemia 09-Nov-1996 active
Ischemic heart disease 06-Oct-1990 active
Metabolic syndrome X 13-Sep-1986 active
Hypertriglyceridemia 13-Sep-1986 active
Type 2 diabetes mellitus 07-Sep-1985 active
Anemia 21-May-1966 active
Prediabetes 28-Apr-1962 active
Essential hypertension 05-Apr-1958 active

Medication list

No known medications

Immunizations list

Vaccine Date
Influenza virus antigen only vaccine product 17-Aug-2024
SARS-CoV-2 mRNA vaccine 08-May-2021
Clostridium tetani toxoid antigen adsorbed only vaccine product 08-Feb-2020

Procedure History list

Procedure Date Reason
Medication reconciliation 05-Jul-2025 -
Assessment of health and social care needs 05-Jul-2025 -
Assessment using Morse Fall Scale 05-Jul-2025 -
Screening for domestic abuse 08-Mar-2025 -
Depression screening 08-Feb-2025 -
Assessment of anxiety 08-Feb-2025 -
Depression screening using Patient Health Questionnaire Two-Item score (procedure) 08-Feb-2025 -
Patient discharge 24-Mar-2024 -
Hospice care 23-Mar-2024 -
Notifications 10-Feb-2024 -
Certification procedure 10-Feb-2024 -
Initial patient assessment 10-Feb-2024 -
Development of individualized plan of care 10-Feb-2024 -
Depression screening using PHQ-9 (Patient Health Questionnaire 9) score 30-Apr-2022 -
Pre-discharge assessment 15-Aug-2021 -
Discharge from skilled nursing facility (procedure) 15-Aug-2021 -
Occupational therapy 14-Aug-2021 -
Nursing care/supplementary surveillance 14-Aug-2021 -
Physical therapy procedure 13-Aug-2021 -
Professional / ancillary services care 12-Aug-2021 -
Care regimes assessment 26-Jul-2021 -
Radiography of humerus 24-Jul-2021 -
History AND physical examination 24-Jul-2021 -
Bone immobilization 24-Jul-2021 Fracture of forearm
Bone density scan 31-Mar-2018 Fracture of forearm

Allergies and Intolerances

Allergy/Intolerance Onset Date Status Type Reaction
Inadequate digital access affecting health care 2025-12-11 active environment

Care Plan

Active Planned Care / Goals Start Date Reason
Dementia management 17-Oct-2014 Alzheimer's disease (disorder)
  • Maintain or slow decline in cognitive function as measured by MMSE.
  • Preserve ability to perform basic activities of daily living (ADLs) as measured by Barthel Index.
  • Reduce frequency and severity of behavioral and psychological symptoms as measured by NPI.
  • Achieve at least 80% adherence to prescribed dementia medication regimen.
Care plan 02-Mar-2014 -
Discharge care plan 17-May-2011 -
Diabetes self management plan 28-Apr-1962 Prediabetes
  • Patient will implement and maintain a diabetes self-management plan including diet, exercise, and medication adherence to optimize glycemic control.
  • Achieve and maintain HbA1c below 7.0% as part of diabetes self-management.
  • Maintain fasting blood glucose between 80 and 130 mg/dL.
  • Maintain blood pressure below 140/90 mmHg as part of diabetes self-management.
  • Maintain LDL cholesterol below 100 mg/dL as part of diabetes self-management.
Lifestyle education regarding hypertension 05-Apr-1958 Essential hypertension (disorder)
  • Achieve and maintain systolic blood pressure below 130 mm[Hg] through lifestyle modification.
  • Achieve and maintain diastolic blood pressure below 80 mm[Hg] through lifestyle modification.
  • Reduce dietary sodium intake to less than 2.3 grams per day as part of hypertension management.
  • Engage in at least 150 minutes of moderate-intensity aerobic physical activity per week to help control blood pressure.
Immunization Recommendation Due Date Reason
Vaccine product containing only Influenza virus antigen (medicinal product) 01-Oct-2025 Annual seasonal influenza vaccination

Vital Signs

Vital Signs 2025-07-19 2025-07-05
Body Height 179.8 cm 179.8 cm
Pain severity - 0-10 verbal numeric rating [Score] - Reported 4 {score} 4 {score}
Body Weight 90.1 kg 90.1 kg
Body mass index (BMI) [Ratio] 27.9 kg/m2 27.9 kg/m2
Diastolic Blood Pressure 85 mm[Hg] 87 mm[Hg]
Systolic Blood Pressure 141 mm[Hg] 129 mm[Hg]
Heart rate 81 /min 79 /min
Respiratory rate 14 /min 13 /min

Relevant diagnostic tests/laboratory data

Recent Lab Observations 19-JUL-2025 Reference Range Unit
Glucose [Mass/volume] in Serum or Plasma 66.4 L 70 - 140 mg/dL
Urea nitrogen [Mass/volume] in Serum or Plasma 16.6 7 - 20 mg/dL
Creatinine [Mass/volume] in Serum or Plasma 1.8 H 0.9 - 1.3 mg/dL
Calcium [Mass/volume] in Serum or Plasma 9.5 8.5 - 10.5 mg/dL
Sodium [Moles/volume] in Serum or Plasma 141.8 135 - 145 mmol/L
Potassium [Moles/volume] in Serum or Plasma 4.1 3.5 - 5.1 mmol/L
Chloride [Moles/volume] in Serum or Plasma 101.6 98 - 114 mmol/L
Carbon dioxide, total [Moles/volume] in Serum or Plasma 22.2 22 - 29 mmol/L
Appearance of Urine Cloudy urine
Odor of Urine Urine smell ammoniacal
Clarity of Urine Translucent
Color of Urine Brown color
Glucose [Mass/volume] in Urine by Test strip 2.2 H 0 - 1 mg/dL
Glucose [Presence] in Urine by Test strip ++
Bilirubin.total [Mass/volume] in Urine by Test strip 0.7 0.1 - 1.2 mg/dL
Bilirubin.total [Presence] in Urine by Test strip Finding of bilirubin in urine
Ketones [Mass/volume] in Urine by Test strip 17.0 0 - 20 mg/dL
Ketones [Presence] in Urine by Test strip Urine ketone test = +
Specific gravity of Urine by Test strip 1.0 L 1.005 - 1.03 {nominal}
pH of Urine by Test strip 6.0 4.5 - 7.5 pH
Protein [Mass/volume] in Urine by Test strip 196.3 H 0 - 14 mg/dL
Protein [Presence] in Urine by Test strip Urine protein test = ++
Nitrite [Presence] in Urine by Test strip Urine nitrite negative
Hemoglobin [Presence] in Urine by Test strip Urine blood test = negative
Leukocyte esterase [Presence] in Urine by Test strip Urine leukocyte test negative
Hemoglobin A1c/Hemoglobin.total in Blood 5.5 4 - 6 %
Glucose [Mass/volume] in Blood 66.4 L 70 - 140 mg/dL
Urea nitrogen [Mass/volume] in Blood 16.6 7 - 20 mg/dL
Creatinine [Mass/volume] in Blood 2.0 H 0.9 - 1.3 mg/dL
Calcium [Mass/volume] in Blood 9.5 8.5 - 10.5 mg/dL
Sodium [Moles/volume] in Blood 141.8 135 - 145 mmol/L
Potassium [Moles/volume] in Blood 4.1 3.5 - 5 mmol/L
Chloride [Moles/volume] in Blood 101.6 98 - 110 mmol/L
Carbon dioxide, total [Moles/volume] in Blood 22.2 L 24 - 29 mmol/L
Cholesterol [Mass/volume] in Serum or Plasma 162.6 125 - 239 mg/dL
Triglyceride [Mass/volume] in Serum or Plasma 145.6 10 - 200 mg/dL
Cholesterol in LDL [Mass/volume] in Serum or Plasma by Direct assay 73.4 0 - 130 mg/dL
Cholesterol in HDL [Mass/volume] in Serum or Plasma 60.1 40 - 100 mg/dL
Microalbumin/Creatinine [Mass Ratio] in Urine 28.9 3 - 30 mg/g

Device Use

Device Date (since)
Blood glucose meter (physical object) 28-Apr-1962